Back to search results

Preventing Relapse for Myeloid Malignancies After Transplant

This study is looking at whether using maintenance therapy (a treatment given after initial therapy to prevent cancer from returning) based on specific test results can help prevent relapse in people with myeloid malignancies (cancers of the blood and bone marrow) like acute myeloid leukemia or myelodysplastic syndromes. You would be eligible if you are 18 or older and have one of these conditions. Before your allogeneic hematopoietic cell transplant (a type of stem cell transplant), doctors will check for measurable residual disease (MRD), which means a small number of cancer cells still present. Depending on these test results, you may or may not be recommended to receive maintenance therapy after your transplant. The main goal is to see how many people are relapse-free one year after their transplant. The study is currently unclear on its recruitment status and plans to enroll 450 participants.

Study design
This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It aims to enroll 450 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures relapse-free survival at one year, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07572929

A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Medical College of Wisconsin
~450 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Maintenance TherapyNo intervention

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with relapse-free survival
Measured over One Year

Conditions

Myeloid Disorders
Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Acute Myeloid Leukemia

Explore related trials

Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Sameem Abedin, MD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Medical College of Wisconsin Cancer Center Clinical Trials Office
[email protected]
866-680-0505 · ext. 8900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years at time of transplant.
Must have a diagnosis of a myeloid malignancy, myelodysplastic syndrome, myeloproliferative neoplasm (including primary or secondary myelofibrosis), or acute myeloid leukemia or biphenotypic acute leukemia.
Pre-transplant disease assessment must include at least one:
Immunophenotypic assessment by flow for aberrant blasts
NGS to identify persistence of malignant clones using a standard clinically available assay
PCR based measurement of prior identified mutations (if applicable)
Ability to understand a written informed consent document, and the willingness to sign it.

What this trial measures

  • Number of subjects with relapse-free survivalOne Year

    All patients will have standard histological analysis of bone marrow biopsies done post-transplant after engraftment, per institutional standard, at one year. For acute leukemia (AML or ALL) or myelodysplastic syndrome, relapse is defined as greater than 5% blasts on histologic analysis of bone marrow biopsy. Among patients assigned to Arm B, institution of any therapy with intent to treat hematologic malignancy will also be considered evidence of relapse.